Alpha-1 Antitrypsin Deficiency

SERPINA1 mutations can reduce the amount of alpha-1-antitrypsin produced or alter how the protein folds. These changes create two linked consequences: inadequate protection in the bloodstream and, in severe variants, retention of misfolded protein within liver cells. The specific molecular effect therefore influences whether lung vulnerability, liver injury, or both become prominent concerns.

Alpha-1-antitrypsin normally limits excessive protease activity in the lungs. When too little reaches the bloodstream, neutrophil elastase can act without adequate restraint and degrade connective tissue in the alveoli, the small air spaces responsible for gas exchange. This tissue damage helps explain the potential development of emphysema and connects the molecular defect to impaired lung structure.

Misfolding creates a two-site disease process. In liver cells, altered alpha-1-antitrypsin may accumulate and contribute to liver injury, while reduced release into the bloodstream leaves lung tissue less protected from neutrophil elastase. Evaluating both organs is therefore important because the same inherited protein abnormality can produce complications through retention in one tissue and deficiency in another.

Evaluation combines several complementary approaches rather than relying on one result. Genetic testing examines SERPINA1, serum protein measurement assesses the circulating alpha-1-antitrypsin level, and pulmonary and hepatic assessments evaluate organ effects. Together, these methods help connect an inherited molecular change with its protein-level consequence and determine whether lung or liver complications require monitoring.

Pulmonary and hepatic assessments show how the deficiency is affecting the body over time. Lung evaluation helps identify consequences of inadequate protection against protease activity, while liver evaluation addresses possible injury associated with intracellular protein accumulation. Repeated or targeted assessment can support monitoring, reveal complications, and guide management focused on the organs at risk.

Augmentation therapy is one management option for reducing complications associated with inadequate alpha-1-antitrypsin protection, while avoiding smoking removes an important preventable threat to vulnerable lung tissue. These measures are used alongside targeted management and medical monitoring rather than as substitutes for evaluation. Their relevance is greatest when care aims to limit progression of pulmonary or hepatic complications.